We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Neurotech’s Implant for Macular Telangiectasia Sees Positive Phase 3 Results
Neurotech’s Implant for Macular Telangiectasia Sees Positive Phase 3 Results
Neurotech Pharmaceuticals has announced positive phase 3 topline results from two trials evaluating its NT-501 eye implant for patients with macular telangiectasia type 2 (MacTel), which makes the results the first to show preservation of photoreceptors with a novel ophthalmic neuroprotectant therapy, according to the company.